Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer

Cancer Immunology Immunotherapy

Volumn 48, Issue 2-3, 1999, Pages 147-152

  Yamada, Akira ^a   Kawano, Koichiro ^b   Harashima, Nanae ^b   Niiya, Fumihiko ^b   Nagai, Kouji ^b   Kobayashi, Terutada ^b   Mine, Takashi ^b   Ushijima, Kimio ^a   Nishida, Takashi ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

Cytotoxic T lymphocytes; HLA restriction; Ovarian cancer; Tumor antigen

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENOTYPE; HLA SYSTEM; HOST RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR CLONING; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; COS CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON TYPE II; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RIBONUCLEOPROTEINS, SMALL NUCLEAR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032991328     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050559     Document Type: Article

References (24)

1. Barouch D, Friede T, Stevanovic S, Tussey L, Smith K, Rowland-Jones S, Braud V, McMichael A, Rammensee HG (1995) HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 182:1847
2. Boon T, Cerottini JC, Van Den Eynde B, Van Der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
3. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethe B (1996) A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 26:224
4. Ferrini, S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L (1985) Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 36:337
5. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109
6. Imai Y, Shichijo S, Yamada A, Katayama T, Yano H, Itoh K (1995) Sequence analysis of MAGE gene family encoding human tumor-rejection antigens. Gene 160:287
7. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T (1992) In HLA 1991, voll. Oxford Scientific Publications, Oxford
8. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS (1991) Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51:4257
9. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucine core peptides. J Immunol 151:3693
10. Itoh K, Hayashi A, Toh Y, Imai Y, Yamada A, Nishida T, Shichijo S (1997) Development of cancer vaccine by tumor rejection antigens. Int Rev Immunol 14:153
11. Kawakami Y, Robbins PF, Rosenberg SA (1996) Human melanoma antigens recognized by T lymphocytes. Keio J Med 45:100
12. Kaye SB (1996) Ovarian cancer, from the laboratory to the clinic challenges for the future. Ann Oncol 7:9
13. Date Y, Kimura A, Kato H, Sasazuki T (1996) DNA typing of the HLA-A gene Tissu Antigens 47:93
14. Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T, Itoh K (1995) HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 55:4248
15. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD, Eberlein TJ (1993) HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 151:5481
16. Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ (1993) T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 151:5472
17. + CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 152:4993
18. Rieber EP, (1989): In Knapp K, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, Von Den Borne AEGKR (eds) Leukocyte typing IV: wight cell differentiation antigens. Oxford University Press, New York, p 229
19. Shichijo S, Tsunosue R, Masuoka K, Natori H, Tamai M, Miyajima J, Sagawa K, Itoh K (1995) Expression of MAGE gene family in human lymphocytic leukemia. Cancer Immunol Immunother 41:95
20. Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277
21. Sudo T, Kamikawaji N, Kimura A, Date Y, Savoie CJ, Nakashima H, Furuichi E, Kuhara S, Sasazuki T (1995) Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 155:4749
22. Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T, Ito K (1995) Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 64:388
23. Yamada A, Hara A, Inoue M, Kamizono S, Higuchi T, Itoh K (1997) β2-Integrin-mediated signal up-regulates counterreceptor ICAM-1 expression on human monocytic cell line THP-1 through tyrosine phosphorylation. Cell Immunol 178:9
24. Yoshino I, People GE, Goedegebuure PS, Maziarz R, Eberlein TJ (1994) Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393